Pictet Asset Management Holding SA Has $1.77 Million Stake in Medpace Holdings, Inc. $MEDP

Pictet Asset Management Holding SA reduced its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 61.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,686 shares of the company’s stock after selling 5,757 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Medpace were worth $1,770,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. NewEdge Advisors LLC raised its holdings in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after buying an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after acquiring an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Medpace during the second quarter worth $296,000. Finally, M&T Bank Corp lifted its position in Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on MEDP shares. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Robert W. Baird cut their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Royal Bank Of Canada reduced their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Finally, Barclays dropped their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $467.08.

Medpace Stock Performance

Shares of MEDP stock opened at $557.60 on Monday. Medpace Holdings, Inc. has a 1 year low of $306.70 and a 1 year high of $628.92. The firm’s fifty day moving average price is $453.88 and its two-hundred day moving average price is $496.19. The firm has a market capitalization of $15.93 billion, a P/E ratio of 35.05, a PEG ratio of 2.83 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.